References
- Sabra A., Bonnar J. Haemostatic changes induced by 50 μg and 30 μg oestrogen/progestogen oral contraceptives. J. Reprod. Med. 1983; 28: 85–91
- Meade T. W. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am. J. Obstet. Gynecol. 1988; 158: 1646–52
- Daly L., Bonnar J. Comparative studies of 30 μg ethinyloestradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. J. Obstet. Gynecol. 1990; 163: 430–7
- Basdevant A., Conard J., Pelissier C., Guyene T. T., Lapousterle C., Mayer M., Guy-Grand B., Degrelle H. Haemostatic and metabolic effects of lowering the ethinyloestradiol dose from 30 μg to 20 μg in oral contraceptives containing desogestrel. Contraception 1993; 48: 193–204
- Melis G. B., Fruzetti F., Nicoletti I., Ricci C., Lammers P., Atsma W. J., Fioretti P. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinyloestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991; 43(1)23–31
- Peterson K. R., Sidelman J., Skouby S. O., Jespersen J. Effects of monophasic low dose oral contraceptives on fibrin formation and resolution in young women. Am. J. Obstet. Gynecol. 1993; 168: 32–8
- Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am. J. Obstet. Gynecol. 1994; 170: 1523–7